RE: Genmab on the hook!!!15 Sep 2025 06:46
Hi TF
Sorry to use Chat gpt to reply but it puts it better than I can:
Yes — you can absolutely frame Scancell’s creation of GlyMab Therapeutics as a defensive move against a potential low-ball takeover bid for the entire company. Let’s build that case step by step:
1. Context: undervaluation risk
Scancell’s market cap (~£90–100m) is far below many analyst risk-adjusted valuations (~£311m rNPV).
With GlyMab alone potentially worth £200–300m in an acquisition (and more if SC134 succeeds clinically), there’s a clear mismatch.
That undervaluation makes Scancell vulnerable to a low offer for the whole company — especially from a partner like Genmab, who already has exposure to GlyMab.
2. Why creating GlyMab Therapeutics helps defend against this
a) Ring-fencing key assets
By placing the antibody platform in a separate subsidiary, Scancell can prevent a predator from gaining control of all platforms (cancer vaccines, Moditope, GlyMab) in a single cheap buyout.
Any acquirer targeting GlyMab specifically would need to negotiate for that entity, not swoop in on Scancell’s depressed AIM valuation.
b) Value separation and transparency
A standalone GlyMab entity can be valued independently of Scancell’s other platforms.
This makes it harder for a bidder to argue that Scancell as a whole should be valued only on its vaccine business while getting GlyMab “for free.”
c) Partnership flexibility
A clean GlyMab vehicle allows Scancell to cut separate licensing, funding, or JV deals.
If Genmab (or another pharma) wants more GlyMab exposure, they must negotiate at arm’s length with the subsidiary — not exploit Scancell’s weak market cap.
d) Poison-pill effect
If Scancell accepts external investment directly into GlyMab Therapeutics, it dilutes the possibility of a whole-company buyout.
Any predator would need to buy out not just Scancell shareholders but also GlyMab minority investors. That raises cost and complexity, deterring opportunistic bids.
3. Strategic signalling
By carving out GlyMab, Scancell signals to the market:
“We believe this platform has independent, material value.”
“We are prepared to crystallise that value outside of Scancell’s share price if necessary.”
This strengthens its negotiating hand against any buyer that comes in with a lowball offer.
4. Precedents in biotech
Many small biotechs have used spin-outs or subsidiaries to protect crown-jewel assets when the parent company looked undervalued (e.g., Immunocore’s separate entity for platform IP before IPO).
It’s a recognised defensive tactic in life sciences M&A.
✅ Case summary:
Scancell establishing GlyMab Therapeutics can indeed be seen as a defensive manoeuvre to:
Highlight GlyMab’s value independently,
Prevent opportunistic low-valuation takeovers of the parent,
Increase negotiating leverage with pharma partners like Genmab,
And ensure Scancell s
Sign In
Follow the stocks
